FLGT Key Statistics, Chart & Performance
The current stock price of FLGT is 28.48 USD. In the past month the price increased by 24.48%. In the past year, price increased by 41.76%.
FLGT Latest News, Press Relases and Analysis
FLGT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.95 | 95.21B | ||
| CI | THE CIGNA GROUP | 9.51 | 72.21B | ||
| LH | LABCORP HOLDINGS INC | 16.8 | 22.03B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 116.66 | 21.46B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.71 | 20.31B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.65B | ||
| DVA | DAVITA INC | 12.81 | 8.35B | ||
| HIMS | HIMS & HERS HEALTH INC | 68.65 | 8.44B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 34.43 | 6.33B | ||
| CHE | CHEMED CORP | 19.58 | 6.10B | ||
| RDNT | RADNET INC | 209.11 | 6.13B | ||
| OPCH | OPTION CARE HEALTH INC | 20.31 | 4.80B |
Related stock screener links
About FLGT
Company Profile
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,313 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Company Info
FULGENT GENETICS INC
4399 Santa Anita Ave
El Monte CALIFORNIA 91780 US
CEO: Ming Hsieh
Employees: 1313
Phone: 16263500537
FULGENT GENETICS INC / FLGT FAQ
Can you describe the business of FULGENT GENETICS INC?
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,313 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
What is the current price of FLGT stock?
The current stock price of FLGT is 28.48 USD. The price increased by 0.28% in the last trading session.
Does FLGT stock pay dividends?
FLGT does not pay a dividend.
What is the ChartMill technical and fundamental rating of FLGT stock?
FLGT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of FULGENT GENETICS INC (FLGT)?
The PE ratio for FULGENT GENETICS INC (FLGT) is 98.21. This is based on the reported non-GAAP earnings per share of 0.29 and the current share price of 28.48 USD.
Would investing in FULGENT GENETICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FLGT.
Can you provide the upcoming earnings date for FULGENT GENETICS INC?
FULGENT GENETICS INC (FLGT) will report earnings on 2026-02-26, after the market close.
FLGT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FLGT. When comparing the yearly performance of all stocks, FLGT is one of the better performing stocks in the market, outperforming 90.91% of all stocks.
FLGT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FLGT. The financial health of FLGT is average, but there are quite some concerns on its profitability.
FLGT Financial Highlights
Over the last trailing twelve months FLGT reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS decreased by -60.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.54% | ||
| ROE | -3.82% | ||
| Debt/Equity | 0 |
FLGT Forecast & Estimates
9 analysts have analysed FLGT and the average price target is 34.34 USD. This implies a price increase of 20.58% is expected in the next year compared to the current price of 28.48.
For the next year, analysts expect an EPS growth of -172.16% and a revenue growth 12.97% for FLGT